NEW YORK, Aug. 20, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) presents its annual fall conference, the 14th International Conference on Alzheimer's Drug Discovery taking place on September 9-10, 2013 at the Hyatt Regency in Jersey City, NJ, across the Hudson River from New York City.

This annual conference brings together academic and industry scientists conducting drug discovery and development for Alzheimer's disease and related dementias. The ADDF's funded investigators and top level scientists in the field will present on their current drug discovery and clinical development programs. The conference offers ample opportunities for collaboration and partnering. Conference participants can expect to interact with senior and emerging professionals in the field of therapeutic development for neurodegenerative diseases and will have ample opportunity to network with industry researchers, exhibitors, private investors and other professionals. Participants will also be introduced to the ADDF ACCESS program which was launched in 2012 to provide the scientific community with access to an online marketplace of CROs, educational resources, consultants, collaborators and industry partners.

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org) The mission of the Alzheimer's Drug Discovery Foundation (ADDF) is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. The ADDF has granted more than $60 million to fund almost 400 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries.